Ensysce Biosciences, Inc. key statistics and ratios

In fiscal 2025, Ensysce Biosciences, Inc. had an operating margin of -202.1%, debt equal to 9.5% of equity and a current ratio of 1.59. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ensysce Biosciences, Inc.: financial ratios, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Operating margin	−41.0%	−562.7%	−959.9%	−480.5%	−129.2%	−202.1%	−281.3%
Net margin	109.7%	−846.4%	−994.1%	−476.4%	−153.3%	−200.8%	−280.5%
Free-cash-flow margin	—	—	—	—	—	−156.5%	—
Return on assets	>999%	−356.5%	−225.0%	−247.3%	−192.3%	−156.0%	−242.5%
Asset turnover	11.17	0.42	0.23	0.52	1.25	0.78	0.86
Current ratio	0.05	0.95	0.56	0.69	2.42	1.59	0.70
Debt to equity	—	—	—	—	8.1%	9.5%	—
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	n/m	n/m	n/m	n/m
Effective tax rate	5.4%	—	—	—	—	—	—
R&D as % of revenue	111.7%	132.8%	786.1%	340.2%	138.6%	204.8%	275.2%
SG&A as % of revenue	29.4%	529.9%	—	—	—	—	—
Capital spending as % of revenue	—	—	—	—	—	2.4%	—

US$ thousands unless shown otherwise. Fiscal quarters.

Ensysce Biosciences, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Operating margin	18.9%	−274.3%	−149.1%	−127.6%	−758.7%	−147.8%	−370.7%	−221.3%
Net margin	19.4%	−273.4%	−147.4%	−126.4%	−756.3%	−147.0%	−370.1%	−220.8%
Free-cash-flow margin	—	—	—	—	—	−81.1%	—	−168.6%
Current ratio	3.24	2.42	2.50	2.10	1.27	1.59	0.71	0.70
R&D as % of revenue	49.5%	291.7%	142.9%	140.2%	599.2%	191.9%	348.3%	212.3%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 3 checks passed · June 30, 2026

What it owns · $3m

Short-term assets $3mLonger-term assets $0m

What it owes, and who funded it · $4m

Short-term liabilities $4mLonger-term liabilities $0mShareholders' equity $-1m

Short-term assets cover short-term liabilities $3m of assets due within a year against $4m of liabilities due within a year.
Short-term assets cover long-term liabilities $3m short-term assets against $0 of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$13m against $15,994 of interest.

From Ensysce Biosciences, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ENSC vs OCGN ENSC vs TRDA CRIS vs ENSC CAMP vs ENSC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ensysce Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ensysce Biosciences, Inc.